Verapamil and beta cell function in adults with recent-onset type 1 diabetes

• Published in: Nature medicine Vol. 24; no. 8; pp. 1108 - 1112
• Main Authors: Ovalle, Fernando, Grimes, Tiffany, Xu, Guanlan, Patel, Anish J, Grayson, Truman B, Thielen, Lance A, Li, Peng, Shalev, Anath
• Format: Journal Article
• Language: English
• Published: United States Nature Publishing Group 01.08.2018
• Subjects: Adult; Adults; Antihypertensives; Beta cells; Blood Pressure - drug effects; Calcium; Calcium channels; Clinical trials; Diabetes; Diabetes mellitus; Diabetes mellitus (insulin dependent); Diabetes Mellitus, Type 1 - drug therapy; Diabetes Mellitus, Type 1 - pathology; Diabetes Mellitus, Type 1 - physiopathology; Glucose; Heart Rate - drug effects; Humans; Insulin; Insulin - metabolism; Insulin-Secreting Cells - drug effects; Insulin-Secreting Cells - pathology; Pancreas; Pathogenesis; Proteins; Thioredoxin; Verapamil; Verapamil - pharmacology; Verapamil - therapeutic use

Pancreatic beta cell loss is a key factor in the pathogenesis of type 1 diabetes (T1D), but therapies to halt this process are lacking. We previously reported that the approved antihypertensive calcium-channel blocker verapamil, by decreasing the expression of thioredoxin-interacting protein, promot...